Ipsen (FR:IPN) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ipsen has revealed promising new data from the Phase III ELATIVE trial, showing that its experimental drug elafibranor significantly slows disease progression and improves itch-related quality of life in patients with primary biliary cholangitis (PBC). After 78 weeks, 70% of patients treated with elafibranor met the composite endpoint of disease progression slowdown, contrasting sharply with 0% in the placebo group. These results, presented at the EASL congress, demonstrate elafibranor’s potential as a first-in-class PPAR agonist treatment option for PBC, a rare autoimmune liver disease.
For further insights into FR:IPN stock, check out TipRanks’ Stock Analysis page.